Last Updated on October 15, 2024 by The Health Master
Glenmark Pharmaceuticals yesterday said it has received approval from the US health regulator to market Nintedanib capsules, used in the treatment of idiopathic pulmonary fibrosis and non-small cell lung cancer, in the American market.
The Mumbai-based drug major has received tentative approval from the US Food and Drug Administration (USFDA) to market the product in the strength of 100 and 150 mg, Glenmark Pharmaceuticals said in a statement.
The company’s product is the generic version of Boehringer Ingelheim Pharmaceuticals Inc’s Ofev capsules.
According to IQVIA sales data for the 12-month period ending April 2021, the Ofev capsules (100 mg and 150 mg) had achieved annual sales of around $1.6 billion.
USFDA okays Tocilizumab for treatment of Covid-19
Zydus Cadila gets tentative nod from USFDA for Pemetrexed for Injection
Cipla gets USFDA nod for Inhalation product
Zydus Cadila gets tentative nod from USFDA for Fingolimod Capsules
Alkem gets two observations from USFDA for USA plant
Lupin gets USFDA nod for treatment of Kidney patient
Latest Notifications: DMROA (Drugs and Magic Remedies Act)
Copyright – An article (Part-1)
FDA takes action against 115 offenders for black marketing of C-19…
DIPSAR to organize FDP for Pharmacy Colleges
Pfizer stops distribution of Anti Smoking Drug
PCI releases draft syllabus for Diploma in Pharmacy
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
